Search for Terms or Answers
ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of my favorite presentations from todays Plenary I session at ACR Convergence. Two of five plenary abstracts were about weight loss, one was about artificial intelligence, and two offered new mechanistic insights with therapeutic implications.
One of the most common questions I receive in my vasculitis clinic is one of the most difficult to answer: “When can we stop rituximab?” While we know everyone needs therapy for at least one year and have reasonably good data for 18 months, whether folks should continue after that remains an open question. That is why I was especially excited to see a post hoc analysis of RITAZAREM, which followed patients for up to 48 months from enrollment
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
